{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06156241",
            "orgStudyIdInfo": {
                "id": "HSC-MS-23-xxxx"
            },
            "organization": {
                "fullName": "The University of Texas Health Science Center, Houston",
                "class": "OTHER"
            },
            "briefTitle": "Stem Cell Study for Long COVID-19 Neurological Symptoms",
            "officialTitle": "Long COVID: Cord Tissue-Derived Mesenchymal Stromal Cells for Persistent NeuroInflammatory Symptoms",
            "acronym": "COVID-19",
            "therapeuticArea": [
                "Rare Diseases"
            ],
            "study": "stem-cell-study-for-long-covid-neurological-symptoms"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-11",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-01",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-02",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-11-17",
            "studyFirstSubmitQcDate": "2023-11-29",
            "studyFirstPostDateStruct": {
                "date": "2023-12-05",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-11-29",
            "lastUpdatePostDateStruct": {
                "date": "2023-12-05",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR_INVESTIGATOR",
                "investigatorFullName": "Charles Cox",
                "investigatorTitle": "The George and Cynthia Mitchell Distinguished Chair in Neurosciences Director, Children's Program in Regenerative Medicine Professor, Departments of Surgery and Pediatric Surgery UTHealth, McGovern Medical School at Houston",
                "investigatorAffiliation": "The University of Texas Health Science Center, Houston"
            },
            "leadSponsor": {
                "name": "Charles Cox",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "CBR Systems, Inc.",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this research study is to test the safety and benefit of a human cord blood derived stem cell infusion as a treatment for individuals with post COVID-19 neurological problems. Participants in the study will have 6 clinic visits over a 12 to 14 mo. period with each visit lasting 2 to 6 hours. Participants will receive 1 stem cell infusion at study visit #3. Participants will have a brain PET and MRI scan at the baseline and 6mo. post-infusion visits. Follow-up safety assessments will be conducted at 6mo. and 1yr. after the stem cell infusion.",
            "detailedDescription": "This is a non-randomized, Phase 1/2a dose escalation study using allogenic cord tissue MSC's in adults with chronic neurological symptoms following an acute COVID-19 infection."
        },
        "conditionsModule": {
            "conditions": [
                "Post-Acute COVID-19 Syndrome"
            ],
            "keywords": [
                "Post COVID-19 Neurological Injuries"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Non-Randomized, Phase 1/2a dose escalation using 4X10\\^6/kg, 6X10\\^6/kg and 8X10\\^6/kg and 10X10\\^10/kg cohorts of 3 patients using an adaptive Bayesian design based upon infusional toxicity/safety.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "4x10^6 Cells/kg Dose Group",
                    "type": "EXPERIMENTAL",
                    "description": "This is a adaptive Baysian dose escalation study. The first 3 subjects will receive one stem cell infusion of 4x10\\^6 Cells/kg. If no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose.",
                    "interventionNames": [
                        "Biological: Stem Cell"
                    ]
                },
                {
                    "label": "6x10^6 Cells/kg Dose Group",
                    "type": "EXPERIMENTAL",
                    "description": "The next cohort of 3 subjects will receive one stem cell infusion of 6x10\\^6 Cells/kg.\n\nIf no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose.",
                    "interventionNames": [
                        "Biological: Stem Cell"
                    ]
                },
                {
                    "label": "8x10^6 Cells/kg Dose Group",
                    "type": "EXPERIMENTAL",
                    "description": "The next cohort of 3 subjects will receive one stem cell infusion of 8x10\\^6 Cells/kg.\n\nIf no infusion related AE/SAE are found, the next cohort will receive the next highest stem cell dose.",
                    "interventionNames": [
                        "Biological: Stem Cell"
                    ]
                },
                {
                    "label": "10x10^6 Cells/kg Dose Group",
                    "type": "EXPERIMENTAL",
                    "description": "The last cohort of 3 subjects will receive one infusion of 10x10\\^6 Cells/kg.",
                    "interventionNames": [
                        "Biological: Stem Cell"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "Stem Cell",
                    "description": "Stem cells derived from human cord tissue.",
                    "armGroupLabels": [
                        "10x10^6 Cells/kg Dose Group",
                        "4x10^6 Cells/kg Dose Group",
                        "6x10^6 Cells/kg Dose Group",
                        "8x10^6 Cells/kg Dose Group"
                    ],
                    "otherNames": [
                        "Allogenic Human Cord Tissue Derived Mesenchymal Stromal Cells (hCTMSCs)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Determine the safety and establish the maximum tolerated dose (MTD) of allogenic human cord tissue derived MSCs (hCTMSCs) as determined by infusional toxicity of the cell product.",
                    "description": "Physical Exam",
                    "timeFrame": "Assessed for the first 24 hours after each stem cell infusion."
                },
                {
                    "measure": "Determine the safety and establish the maximum tolerated dose (MTD) of allogenic human cord tissue derived MSCs (hCTMSCs) as determined by infusional toxicity of the cell product.",
                    "description": "Clinical Lab Assessments",
                    "timeFrame": "Assessed for the first 24 hours after each stem cell infusion."
                },
                {
                    "measure": "Determine the safety and establish the maximum tolerated dose (MTD) of allogenic human cord tissue derived MSCs (hCTMSCs) as determined by infusional toxicity of the cell product.",
                    "description": "Vital Signs",
                    "timeFrame": "Assessed for the first 24 hours after each stem cell infusion."
                },
                {
                    "measure": "Determine the safety and establish the maximum tolerated dose (MTD) of allogenic human cord tissue derived MSCs (hCTMSCs) as determined by infusional toxicity of the cell product.",
                    "description": "Subject Report of Adverse Event(s)",
                    "timeFrame": "Assessed for the first 24 hours after each stem cell infusion."
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Investigate if the hCTMSC infusions reduce the neuroinflammatory response following an acute COVID-19 infection as measured by the degree of microglial activation.",
                    "description": "Comparison of Brain PET Scan at baseline visit and at 6 months post-infusion.",
                    "timeFrame": "Baseline visit to 6 months post-infusion."
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Obtain treatment effect estimates on the structural integrity of the corpus callosum measured by changes in fractional anisotropy (FA).",
                    "description": "Comparison of Brain DT-MRI at baseline visit and at 6 month post-infusion.",
                    "timeFrame": "Baseline visit to 6 months post-infusion."
                },
                {
                    "measure": "Obtain treatment effect estimates on the structural integrity of the corpus callosum measured by mean diffusivity (MD). MD is an inverse measure of membrane density, and is sensitive to edema and necrosis.",
                    "description": "Comparison of Brain DT-MRI at baseline visit and at 6 month post-infusion.",
                    "timeFrame": "Baseline visit to 6 months post-infusion."
                },
                {
                    "measure": "Obtain treatment effect estimates on the structural integrity of the corticospinal tracts measured by fractional anisotropy (FA).",
                    "description": "Comparison of Brain DT-MRI at baseline visit and at 6 month post-infusion.",
                    "timeFrame": "Baseline visit to 6 months post-infusion."
                },
                {
                    "measure": "Obtain treatment effect estimates on the structural integrity of the corticospinal tracts measured by mean diffusivity (MD). MD is an inverse measure of membrane density, and is sensitive to edema and necrosis.",
                    "description": "Comparison of Brain DT-MRI at baseline visit and at 6 month post-infusion.",
                    "timeFrame": "Baseline visit to 6 months post-infusion."
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Adults between 18 and 55 years of age.\n2. Documented history of COVID-19 infection with resulting neurological sequela.\n3. Post-Covid-19 Functional Status score of grades 3 or 4.\n4. Chronic neurological symptoms defined as anxiety/depression, pain syndromes, sleep disorders, and /or memory disorders (\"brain fog\") persisting 6 months after an acute COVID-19 infection.\n5. Ability to obtain consent from the subject.\n6. Ability to communicate in English or Spanish (required for validated neurocognitive outcome testing).\n\nExclusion Criteria:\n\n1. Known history of:\n\n   1. intellectual deficiency or psychiatric conditions likely to invalidate our ability to assess changes in cognition or behavior,\n   2. recently treated infection,\n   3. renal disease or altered renal function (screening serum creatinine \\> 1.5 mg/dL),\n   4. hepatic disease or altered liver function (screening SGPT \\> 150 U/L and/or T. Bilirubin \\>1.3 mg/dL),\n   5. cancer,\n   6. immunosuppression (screening WBC \\< 3, 000 cells/ml),\n   7. HIV+,\n   8. chemical or ETOH dependency that in the opinion of the investigator would preclude participation in the study,\n   9. acute or chronic lung disease requiring significant medication/oxygen supplementation,\n   10. bleeding disorders including immune-mediated heparin-induced thrombocytopenia,\n   11. hypercoagulable disorders (Protein C, S, ATIII deficiencies), Factor V Leiden,\n   12. known sensitivity to heparin, Lovenox, and pork products,\n   13. individuals with mechanical prosthetic heart valves.\n2. Pulse oximetry oxygen saturation \\<93% on room air.\n3. Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation.\n4. For women of childbearing potential, a positive pregnancy test at the screening visit or, for both women and men, unwillingness to comply with acceptable methods of birth control during the study.\n5. Previous or concurrent participation in an interventional drug or biological study.\n6. Inability to undergo the diagnostic tests (PET/DT-MRI) or unwilling/unable to cooperate with the diagnostic tests and outcome assessments.\n7. Unwilling or unable to return for follow-up study visits.\n8. Prisoner/Incarcerated.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Charles S. Cox, MD",
                    "role": "CONTACT",
                    "phone": "713.500.7300",
                    "email": "charles.s.cox@uth.tmc.edu"
                },
                {
                    "name": "Carmen Duron, MHA, RN",
                    "role": "CONTACT",
                    "phone": "713.500.7395",
                    "email": "maria.carmen.duron@uth.tmc.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Charles S. Cox, MD",
                    "affiliation": "The Univ. of Tx. Health Science Center- Houston",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "The University of Texas Health Science Center at Houston",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "34265229",
                    "type": "RESULT",
                    "citation": "Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, Haroon S, Price G, Davies EH, Nirantharakumar K, Sapey E, Calvert MJ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med. 2021 Sep;114(9):428-442. doi: 10.1177/01410768211032850. Epub 2021 Jul 15."
                },
                {
                    "pmid": "34913540",
                    "type": "RESULT",
                    "citation": "Cha C, Baek G. Symptoms and management of long COVID: A scoping review. J Clin Nurs. 2024 Jan;33(1):11-28. doi: 10.1111/jocn.16150. Epub 2021 Dec 15."
                },
                {
                    "pmid": "35156065",
                    "type": "RESULT",
                    "citation": "Costas-Carrera A, Sanchez-Rodriguez MM, Canizares S, Ojeda A, Martin-Villalba I, Prime-Tous M, Rodriguez-Rey MA, Segu X, Valdesoiro-Pulido F, Borras R, Peri JM, Vieta E. Neuropsychological functioning in post-ICU patients after severe COVID-19 infection: The role of cognitive reserve. Brain Behav Immun Health. 2022 May;21:100425. doi: 10.1016/j.bbih.2022.100425. Epub 2022 Feb 7."
                },
                {
                    "pmid": "34308300",
                    "type": "RESULT",
                    "citation": "Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021 Aug;38:101019. doi: 10.1016/j.eclinm.2021.101019. Epub 2021 Jul 15."
                },
                {
                    "pmid": "33031513",
                    "type": "RESULT",
                    "citation": "Del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19. JAMA. 2020 Nov 3;324(17):1723-1724. doi: 10.1001/jama.2020.19719. No abstract available."
                },
                {
                    "pmid": "33391730",
                    "type": "RESULT",
                    "citation": "Doykov I, Hallqvist J, Gilmour KC, Grandjean L, Mills K, Heywood WE. 'The long tail of Covid-19' - The detection of a prolonged inflammatory response after a SARS-CoV-2 infection in asymptomatic and mildly affected patients. F1000Res. 2020 Nov 19;9:1349. doi: 10.12688/f1000research.27287.2. eCollection 2020."
                },
                {
                    "pmid": "33755344",
                    "type": "RESULT",
                    "citation": "Graham EL, Clark JR, Orban ZS, Lim PH, Szymanski AL, Taylor C, DiBiase RM, Jia DT, Balabanov R, Ho SU, Batra A, Liotta EM, Koralnik IJ. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 \"long haulers\". Ann Clin Transl Neurol. 2021 May;8(5):1073-1085. doi: 10.1002/acn3.51350. Epub 2021 Mar 30."
                },
                {
                    "pmid": "34790680",
                    "type": "RESULT",
                    "citation": "Hayes LD, Ingram J, Sculthorpe NF. More Than 100 Persistent Symptoms of SARS-CoV-2 (Long COVID): A Scoping Review. Front Med (Lausanne). 2021 Nov 1;8:750378. doi: 10.3389/fmed.2021.750378. eCollection 2021."
                },
                {
                    "pmid": "33347790",
                    "type": "RESULT",
                    "citation": "Higgins V, Sohaei D, Diamandis EP, Prassas I. COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021 Aug;58(5):297-310. doi: 10.1080/10408363.2020.1860895. Epub 2020 Dec 21."
                },
                {
                    "pmid": "33428867",
                    "type": "RESULT",
                    "citation": "Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, Kang L, Guo L, Liu M, Zhou X, Luo J, Huang Z, Tu S, Zhao Y, Chen L, Xu D, Li Y, Li C, Peng L, Li Y, Xie W, Cui D, Shang L, Fan G, Xu J, Wang G, Wang Y, Zhong J, Wang C, Wang J, Zhang D, Cao B. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 Jan 16;397(10270):220-232. doi: 10.1016/S0140-6736(20)32656-8. Epub 2021 Jan 8."
                },
                {
                    "pmid": "27856631",
                    "type": "RESULT",
                    "citation": "Ikawa M, Lohith TG, Shrestha S, Telu S, Zoghbi SS, Castellano S, Taliani S, Da Settimo F, Fujita M, Pike VW, Innis RB; Biomarkers Consortium Radioligand Project Team. 11C-ER176, a Radioligand for 18-kDa Translocator Protein, Has Adequate Sensitivity to Robustly Image All Three Affinity Genotypes in Human Brain. J Nucl Med. 2017 Feb;58(2):320-325. doi: 10.2967/jnumed.116.178996. Epub 2016 Nov 17."
                },
                {
                    "pmid": "34255355",
                    "type": "RESULT",
                    "citation": "Kayaaslan B, Eser F, Kalem AK, Kaya G, Kaplan B, Kacar D, Hasanoglu I, Coskun B, Guner R. Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19. J Med Virol. 2021 Dec;93(12):6566-6574. doi: 10.1002/jmv.27198. Epub 2021 Jul 28."
                },
                {
                    "pmid": "33764478",
                    "type": "RESULT",
                    "citation": "Lemhofer C, Gutenbrunner C, Schiller J, Loudovici-Krug D, Best N, Bokel A, Sturm C. Assessment of rehabilitation needs in patients after COVID-19: Development of the COVID-19-rehabilitation needs survey. J Rehabil Med. 2021 Apr 27;53(4):jrm00183. doi: 10.2340/16501977-2818."
                },
                {
                    "pmid": "33172844",
                    "type": "RESULT",
                    "citation": "Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, Heightman M, Hillman TE, Jacob J, Jarvis HC, Lipman MCI, Naidu SB, Nair A, Porter JC, Tomlinson GS, Hurst JR; ARC Study Group. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021 Apr;76(4):396-398. doi: 10.1136/thoraxjnl-2020-215818. Epub 2020 Nov 10."
                },
                {
                    "pmid": "32934000",
                    "type": "RESULT",
                    "citation": "Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, Gabrilove JL, Sacks H. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid Based Med. 2021 Jun;26(3):107-108. doi: 10.1136/bmjebm-2020-111536. Epub 2020 Sep 15."
                },
                {
                    "pmid": "34676578",
                    "type": "RESULT",
                    "citation": "O'Connor RJ, Preston N, Parkin A, Makower S, Ross D, Gee J, Halpin SJ, Horton M, Sivan M. The COVID-19 Yorkshire Rehabilitation Scale (C19-YRS): Application and psychometric analysis in a post-COVID-19 syndrome cohort. J Med Virol. 2022 Mar;94(3):1027-1034. doi: 10.1002/jmv.27415. Epub 2021 Nov 5."
                },
                {
                    "pmid": "32427134",
                    "type": "RESULT",
                    "citation": "Ogier M, Andeol G, Sagui E, Dal Bo G. How to detect and track chronic neurologic sequelae of COVID-19? Use of auditory brainstem responses and neuroimaging for long-term patient follow-up. Brain Behav Immun Health. 2020 May;5:100081. doi: 10.1016/j.bbih.2020.100081. Epub 2020 May 15."
                },
                {
                    "pmid": "32637987",
                    "type": "RESULT",
                    "citation": "Paterson RW, Brown RL, Benjamin L, Nortley R, Wiethoff S, Bharucha T, Jayaseelan DL, Kumar G, Raftopoulos RE, Zambreanu L, Vivekanandam V, Khoo A, Geraldes R, Chinthapalli K, Boyd E, Tuzlali H, Price G, Christofi G, Morrow J, McNamara P, McLoughlin B, Lim ST, Mehta PR, Levee V, Keddie S, Yong W, Trip SA, Foulkes AJM, Hotton G, Miller TD, Everitt AD, Carswell C, Davies NWS, Yoong M, Attwell D, Sreedharan J, Silber E, Schott JM, Chandratheva A, Perry RJ, Simister R, Checkley A, Longley N, Farmer SF, Carletti F, Houlihan C, Thom M, Lunn MP, Spillane J, Howard R, Vincent A, Werring DJ, Hoskote C, Jager HR, Manji H, Zandi MS. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020 Oct 1;143(10):3104-3120. doi: 10.1093/brain/awaa240."
                },
                {
                    "pmid": "34245450",
                    "type": "RESULT",
                    "citation": "Scherlinger M, Felten R, Gallais F, Nazon C, Chatelus E, Pijnenburg L, Mengin A, Gras A, Vidailhet P, Arnould-Michel R, Bibi-Triki S, Carapito R, Trouillet-Assant S, Perret M, Belot A, Bahram S, Arnaud L, Gottenberg JE, Fafi-Kremer S, Sibilia J. Refining \"Long-COVID\" by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infect Dis Ther. 2021 Sep;10(3):1747-1763. doi: 10.1007/s40121-021-00484-w. Epub 2021 Jul 10."
                },
                {
                    "pmid": "33912905",
                    "type": "RESULT",
                    "citation": "Tran VT, Riveros C, Clepier B, Desvarieux M, Collet C, Yordanov Y, Ravaud P. Development and Validation of the Long Coronavirus Disease (COVID) Symptom and Impact Tools: A Set of Patient-Reported Instruments Constructed From Patients' Lived Experience. Clin Infect Dis. 2022 Jan 29;74(2):278-287. doi: 10.1093/cid/ciab352."
                },
                {
                    "pmid": "33413026",
                    "type": "RESULT",
                    "citation": "Townsend L, Dowds J, O'Brien K, Sheill G, Dyer AH, O'Kelly B, Hynes JP, Mooney A, Dunne J, Ni Cheallaigh C, O'Farrelly C, Bourke NM, Conlon N, Martin-Loeches I, Bergin C, Nadarajan P, Bannan C. Persistent Poor Health after COVID-19 Is Not Associated with Respiratory Complications or Initial Disease Severity. Ann Am Thorac Soc. 2021 Jun;18(6):997-1003. doi: 10.1513/AnnalsATS.202009-1175OC."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000086382",
                    "term": "COVID-19"
                },
                {
                    "id": "D000094024",
                    "term": "Post-Acute COVID-19 Syndrome"
                }
            ],
            "ancestors": [
                {
                    "id": "D000011024",
                    "term": "Pneumonia, Viral"
                },
                {
                    "id": "D000011014",
                    "term": "Pneumonia"
                },
                {
                    "id": "D000012141",
                    "term": "Respiratory Tract Infections"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000018352",
                    "term": "Coronavirus Infections"
                },
                {
                    "id": "D000003333",
                    "term": "Coronaviridae Infections"
                },
                {
                    "id": "D000030341",
                    "term": "Nidovirales Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000094025",
                    "term": "Post-Infectious Disorders"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M16355",
                    "name": "Syndrome",
                    "relevance": "LOW"
                },
                {
                    "id": "M3013",
                    "name": "Post-Acute COVID-19 Syndrome",
                    "asFound": "Post-Acute COVID-19 Syndrome",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2561",
                    "name": "COVID-19",
                    "asFound": "COVID-19",
                    "relevance": "HIGH"
                },
                {
                    "id": "M22023",
                    "name": "Trauma, Nervous System",
                    "relevance": "LOW"
                },
                {
                    "id": "M13904",
                    "name": "Pneumonia",
                    "relevance": "LOW"
                },
                {
                    "id": "M13914",
                    "name": "Pneumonia, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14978",
                    "name": "Respiratory Tract Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20490",
                    "name": "Coronavirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6555",
                    "name": "Coronaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M23685",
                    "name": "Nidovirales Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M3014",
                    "name": "Post-Infectious Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC26",
                    "name": "Wounds and Injuries"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}